Document is current
Any future updates will be listed below
-
Authors
Holtermann, Anne https://orcid.org/0009-0006-7604-9910
Gislon, Mila
Angele, Martin
Subklewe, Marion
von Bergwelt-Baildon, Michael
Lauber, Kirsten
Kobold, Sebastian
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (KO5055-2-1, KO5055/3-1)
Bayerisches Zentrum für Krebsforschung (TANGO)
Elitenetzwerk Bayern (i-Target)
Melanoma Research Alliance (409510)
H2020 Marie Skłodowska-Curie Actions (955575)
Else Kröner-Fresenius-Stiftung (IOLIN)
Deutsche Krebshilfe (AvantCAR.de)
Wilhelm Sander-Stiftung
Ernst Jung Stiftung
German Excellence Initiative
Go-Bio-Initiative
Bayerisches Staatsministerium für Wirtschaft, Infrastruktur, Verkehr und Technologie (m4-Award)
Bundesministerium für Bildung und Forschung
European Research Council (756017, 101100460, 101124203)
SFB-TRR 338/1 (2021–452881907)
Fritz-Bender-Stiftung
José Carreras Leukämie-Stiftung
Hector Stiftung
Bayerische Forschungsstiftung (BAYCELLATOR)
Bruno and Helene Jöster Foundation (360° CAR)
Monika-Kutzner Stuftung
Mildred-Scheel-Doktorandenprogram
Klinikum der Universität München
- License Information
-
More Information
Article History
Accepted: 17 June 2024
First Online: 30 July 2024
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. This study was supported by the Bavarian Cancer Research Center (BZKF) [TANGO to SK], the Deutsche Forschungsgemeinschaft (DFG, KO5055-2-1 and KO5055/3-1 to SK), the international doctoral program ‘i-Target: immunotargeting of cancer’ (funded by the Elite Network of Bavaria; to SK), the Melanoma Research Alliance (grant number 409510 to SK), Marie Sklodowska-Curie Training Network for Optimizing Adoptive T Cell Therapy of Cancer (funded by the Horizon 2020 programme of the European Union; grant 955575 to SK), Else Kröner-Fresenius-Stiftung (IOLIN to AVH and SK), German Cancer Aid (AvantCAR.de to SK), the Wilhelm-Sander-Stiftung (to SK), Ernst Jung Stiftung (to SK), Institutional Strategy LMUexcellent of LMU Munich (within the framework of the German Excellence Initiative; to SE and SK), the Go-Bio-Initiative (to SK), the m4-Award of the Bavarian Ministry for Economical Affairs (to SE and SK), Bundesministerium für Bildung und Forschung (to SE and SK), European Research Council (Starting Grant 756017, PoC Grant 101100460 and CoG 101124203 to SK), by the SFB-TRR 338/1 2021–452881907 (to SK), Fritz-Bender Foundation (to SK), Deutsche José Carreras Leukämie Stiftung (to SK), Hector Foundation (to SK), Bavarian Research Foundation (BAYCELLATOR to SK), the Bruno and Helene Jöster Foundation (360° CAR to SK), the Monika-Kutzner Stiftung (to SK), the Mildred-Scheel-Doktorandenprogram (to MJG).
: Sebastian Kobold has received honoraria from Cymab, Plectonic TCR2 Inc., Miltenyi, Galapagos, Novartis, BMS, and GSK. Sebastian Kobold is an inventor of several patents in the field of immuno-oncology. Sebastian Kobold received license fees from TCR2 Inc. and Carina Biotech. Sebastian Kobold received research support from TCR2 Inc., Tabby Therapeutics, Catalym GmBH, Plectonic GmBH, and Arcus Bioscience for work unrelated to the manuscript. Anne Holtermann, Mila Gislon, Martin Angele, Marion Subklewe, Michael von Bergwelt-Baildon, and Kirsten Lauber have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: No datasets were generated or analyzed during the review article, data that support the findings referenced in this article can be found in their corresponding original referenced study.
: Not applicable.
: AVH: conceptualization and writing. MJG: visualized artwork using Procreate (version 5.3.7; Savage Interactive Pty Ltd, Hobart, TAS, Australia) based on own conception. SK: supervision and editing. All authors read and approved the final manuscript.
